What if you could complete a simple blood test that will tell you if you have a risk of dying in the next 5 to 10 years? Indeed, this type of test would be truly life-saving, enabling people to make immediate lifestyle changes or get into treatment quickly to prevent a gloomy prognosis – and this blood test "not all triggers of mortality" is so far from reality.
A team of Dutch researchers from Leiden University, led by Elaine Slagboom, found 14 biomarkers that are independently associated with mortality in people of all ages. When combined, they reveal an index or risk score that reflects a person's chance of dying in the near future.
"Slave predictors of medium and long-term mortality can be valuable tools in clinical trials and medical decision-making," the authors wrote in the journal. Outdoor communications.
"The associations of these biomarkers were consistent in men and women and across different age groups. Identified biomarkers represent general health at higher ages than specific causes of disease-related deaths. In combination, these biomarkers clearly improve 5- and 10-year mortality risk prediction, compared to conventional risk factors of all ages.
The results are based on data from biobanks around the world, including more than 44,000 people aged 18 to 109 years. During the follow-up to the study, nearly 5,500 participants died.
By examining the data, the researchers were able to find out which biomarkers were most strongly associated with potential mortality – a prime example being glucose. However, some of the markers can be used to assess overall health. For example, the ratio of polyunsaturated fats to total fatty acids is associated with reduced mortality.
Ultimately, the researchers tested the predictive ability of these biomarkers in people of different age groups. Their model suggests that the 14 biomarkers more accurately predict 5- to 10-year mortality risk than other methods.
The discovery that there's a good chance you're going to die in the next five years sounds horrible. For this reason, it is understandable why many would choose to remain without such a test. However, in the medical context, a blood test for mortality risk can mean the difference between performing a risk surgery and employing some other treatment for fragile patients.
In the future, Dutch researchers would like to test how their biomarker result affects patient outcome.
"The currently used metabolism platform may be incorporated into ongoing clinical trials to investigate its value, opening up new research avenues for establishing a metabolic biomarker tool in clinical settings," the authors concluded.